Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to Crizotinib

PURPOSE: The European Organization for Research and Treatment of Cancer (EORTC) clinical phase II trial 90101 "CREATE" showed high antitumor activity of crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK)/ROS1, in patients with advanced inflammatory myofibroblastic tumor (IMFT). H...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	CLINICAL CANCER RESEARCH 2021-12, Vol.27 (24), p.6737-6748
Hauptverfasser:	Lee, Che-Jui, Schoeffski, Patrick, Modave, Elodie, van Wezel, Tom, Boeckx, Bram, Sufliarsky, Jozef, Gelderblom, Hans, Blay, Jean-Yves, Debiec-Rychter, Maria, Sciot, Raf, Bovee, Judith V.M.G, Lambrechts, Diether, Wozniak, Agnieszka
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!